FDA finds no suicide risk with GLP-1s, oral Wegovy draws explosive demand, Lilly's Foundayo launches at $25/month, and a Utah physician is indicted for importing peptides.
Read digest →Landmark GLP-1 pricing drops to $245/mo, Lilly's retatrutide aces Phase 3, and investigations expose peptide quality failures and safety risks.
Read digest →Pinnacle raises $89M for oral peptides matching biologics, cagrilintide shows Phase 3 obesity results, and higher-dose Wegovy achieves 21% weight loss.
Read digest →UK MHRA investigates peptide clinics, GoodRx matches oral semaglutide pricing, FDA approves Eli Lilly oral GLP-1, and India tightens GLP-1 oversight.
Read digest →RFK Jr. moves to reverse FDA peptide ban amid safety pushback; Lilly retatrutide hits Phase 3 endpoints; oral semaglutide may outperform orforglipron.
Read digest →Eli Lilly's oral GLP-1 Foundayo approved in record time; retatrutide hits 28.7% weight loss in Phase 3; semaglutide linked to rare skin condition.
Read digest →FDA approves Eli Lilly's Foundayo, the first small-molecule GLP-1 pill for obesity. GLP-1 drugs show heart and kidney benefits in Type 1 diabetes.
Read digest →FDA expected to lift peptide compounding ban at RFK Jr.'s urging; 30 telehealth firms warned; Novo slashes Ozempic prices in India; UK expands Wegovy prescribing.
Read digest →Retatrutide clears fatty liver in 85%+ of patients, cagrilintide posts Phase 3 obesity results, and Lilly investigates GLP-1s for substance use disorders.
Read digest →PBS covers FDA peptide supplement meeting, oral Wegovy approved on OASIS 4 data, and The Guardian editorial slams RFK Jr.'s peptide deregulation.
Read digest →Landmark study links GLP-1s to reduced addiction risk in 600K+ veterans, J&J's ICOTYDE shows durable psoriasis clearance, and tesamorelin gets new formulation.
Read digest →FDA holds first meeting on peptides as supplement ingredients under RFK Jr., Stanford unveils peptide-to-DNA sequencing, and Skeptic Magazine warns of risks.
Read digest →RFK Jr. signals FDA will lift restrictions on ~14 peptides, Lilly and Novo strike MFN pricing deals, and orforglipron outperforms oral semaglutide.
Read digest →Novo Nordisk cuts US list prices ~50% for 2027, retatrutide hits record 28.7% weight loss in Phase 3, and experts propose 10-year GLP-1 cancer trial.
Read digest →FDA approves oral semaglutide pill and higher Ozempic dose, grants survodutide breakthrough designation for MASH, and oral insulin via cyclic peptides advances.
Read digest →